Premium
In vivo localization of a bispecific antibody which targets human t lymphocytes to lyse human colon cancer cells
Author(s) -
Barr Ian G.,
Miescher Sylvia,
Fliedner Vladimir Von,
Buchegger Franz,
Barras Catherine,
Lanzavecchia Antonio,
Mach JeanPierre,
Carrel Stefan
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430327
Subject(s) - monoclonal antibody , antibody , in vivo , cytolysis , cd3 , microbiology and biotechnology , biology , glycoprotein , cancer research , antigen , in vitro , immunology , cytotoxicity , biochemistry , cd8
A bispecific MAb was derived from the fusion of a hybridoma producing MAb CD3 with a hybridoma producing MAb L‐Dl (which is directed against a 41‐kDa glycoprotein expressed in most gastro‐intestinal and pancreatic carcinomas). Bispecific antibody molecules were isolated from parental antibody molecules by the use of hydroxylapatite‐HPLC and shown to target human cytolytic T lymphocytes, irrespective of their original specificity, to specifically lyse human colon carcinoma cells. Localization studies in vivo using nude mice bearing human colon carcinoma xenografts showed significant accumulation of the HPLC‐purified 125 l‐labelled bispecific antibodies into the tumor compared to 131 l‐labelled control CD3 antibody.